



RESEARCH ARTICLE

Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis

Alex Lewin^{1,5}, Shea Hamilton², Aviva Witkover², Paul Langford², Richard Nicholas³, Jeremy Chataway ⁴, Charles Bangham ²

¹Department of Epidemiology and Biostatistics, Imperial College London, London, UK

²Division of Infectious Diseases, Department of Medicine, Imperial College London, London, UK

³Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK

⁴National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust and Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London, London, UK

⁵Present address: Department of Mathematics, Brunel University, London, UK

v1 First published: N/A, N/A: N/A (doi: N/A)
Latest published: N/A, N/A: N/A (doi: N/A)

Abstract

Background

A major cause of disability in secondary progressive multiple sclerosis (SPMS) is progressive brain atrophy, whose pathogenesis is not fully understood. The objective of this study was to identify protein biomarkers of brain atrophy in SPMS.

Methods

We used surface-enhanced laser desorption-ionization time-of-flight mass spectrometry to carry out an unbiased search for serum proteins whose concentration correlated with the rate of brain atrophy, measured by serial MRI scans over a 2-year period in a well-characterized cohort of 140 patients with SPMS. Protein species were identified by liquid chromatography-electrospray ionization tandem mass spectrometry.

Results

There was a significant ($p < 0.004$) correlation between the rate of brain atrophy and a rise in the concentration of proteins at 15.1 kDa and 15.9 kDa in the serum. Tandem mass spectrometry identified these proteins as alpha-haemoglobin and beta-haemoglobin, respectively. The abnormal concentration of free serum haemoglobin was confirmed by ELISA ($p < 0.001$). The serum lactate dehydrogenase activity was also highly significantly raised ($p < 10^{-12}$) in patients with secondary progressive multiple sclerosis.

Conclusions

An underlying low-grade chronic intravascular haemolysis is a potential source of the iron whose deposition along blood vessels in multiple sclerosis plaques contributes to the neurodegeneration and consequent brain atrophy seen in progressive disease. Chelators of free serum iron will be ineffective in preventing this neurodegeneration, because the iron (Fe^{2+}) is chelated by haemoglobin.

Open Peer Review

Referee Status: Awaiting Peer

Review

Discuss this article

Comments (0)

Corresponding authors: Alex Lewin (Alex.Lewin@brunel.ac.uk), Shea Hamilton (s.hamilton@imperial.ac.uk), Charles Bangham (c.bangham@imperial.ac.uk)

How to cite this article: Lewin A, Hamilton S, Witkover A *et al*. **Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis** Wellcome Open Research , : (doi: [\\$version.doi](#))

Copyright: © 2016 Lewin A *et al*. This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Grant information: This work was supported by the Wellcome Trust [100291]; Medical Research Council [MR K019090]; National Institute of Health Research; University College London Hospitals/UCL Biomedical Research Centre.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: No competing interests were disclosed.

First published: N/A, **N/A:** N/A (doi: N/A)

Introduction

In multiple sclerosis (MS), progressive disease develops in over half of those who present with an initial relapsing phase – secondary progressive MS (SPMS) – but can also present as primary progressive MS (PPMS). Progressive MS, for which there is no clear disease-modifying treatment^{1–3}, accounts for much of the disability and the cost of MS to both the person and the community⁴.

Unlike relapsing-remitting MS (RRMS), where an inflammatory response involving the adaptive immune system leads to episodic neurological deficits, in progressive MS neuroaxonal loss leads to an increasing neurological deficit and brain atrophy^{5,6}. However, in all forms of the disease, both the initiating events and the mechanisms of pathogenesis remain uncertain⁵. Pseudoatrophy may account for some loss of brain volume⁷, but brain atrophy has also been associated with changes in neurofilament levels⁸ and sodium metabolism⁹.

The objective of the present study was to use an unbiased, high-throughput technique to identify protein biomarkers of brain atrophy in a longitudinal cohort of patients with SPMS. We used surface-enhanced laser desorption-ionization time-of-flight (SELDI-TOF) mass spectrometry to analyse serial serum samples from the population that participated in the MS-STAT study (described below)¹, to identify proteins whose abundance was associated with MRI-measured brain atrophy rate. Serum proteomics in MS has previously been investigated in small cross-sectional studies to compare relapsing MS and progressive disease^{10–12}. However, these previous studies were neither designed nor powered to identify correlates of neurodegeneration in SPMS.

We found that the rate of brain atrophy in this cohort was associated with an increase in the concentration of free haemoglobin in the serum. This association was independent of the beneficial effect of simvastatin treatment, which remained significant in the present analysis. An ELISA assay confirmed the presence of abnormal concentrations of free haemoglobin in the serum of patients with SPMS. In addition, the serum lactate dehydrogenase (LDH) activity was significantly greater in patients with SPMS than in three different groups of control subjects. These results suggest that chronic intravascular haemolysis releases haemoglobin into the serum in SPMS; we postulate that this haemoglobin is a source of the abnormal iron deposition along blood vessels in the central nervous system that is associated with neurodegeneration in progressive MS.

Methods

Ethical approval

The study was done in accordance with Good Clinical Practice and the Declaration of Helsinki. The protocol was approved by the UK National Research Ethics Service (Berkshire Research Ethics Committee; reference 07/Q1602/73), and every patient gave written informed consent before entering the study.

Subjects

The MS-STAT clinical trial was registered with ClinicalTrials.gov (NCT00647348) and has been described in detail elsewhere¹. In this phase 2 placebo-controlled double-blind trial, 140 patients with SPMS were randomized 1:1 to simvastatin 80 mg/day (40 mg for

the first month) or matched placebo. The patients were in trial for 2 years. The primary outcome was change in whole brain volume as measured by the Brain Boundary Shift Integral (BBSI), with MRI data acquired at baseline, 12 months and 25 months; the last MRI scan (25 months) was carried out 1 month after last medication to minimize any potential artefactual changes in volume¹. Simvastatin treatment resulted in a highly statistically significant 43% reduction in the annualized rate of brain atrophy¹, and significant changes were also seen in certain clinician- and patient-reported outcome measures. As control groups in the haemoglobin assays, we studied healthy adult volunteers (n=20); patients with human T-lymphotropic virus (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), which closely resembles chronic spinal forms of multiple sclerosis (n=20); and asymptomatic HTLV-1 carriers (n=20).

Protein profiling of serum by SELDI-TOF mass spectrometry

SELDI-TOF mass spectrometry was performed on 475 serum samples collected at baseline, 6 month, 12 months and 24 months. Samples were randomized, and staff were blinded to the treatment arms. CM10 ProteinChip arrays (Bio-Rad Laboratories) were primed with binding buffer (50 mM ammonium acetate, 0.01% Triton X-100, pH 4.0) and incubated at room temperature (RT) for 5 min. A 1:10 dilution of serum in binding buffer was then applied to the array and incubated at RT for 1 hr. The arrays were washed twice with binding buffer and deionized water. Saturated sinapinic acid (0.7 µL) was applied twice to each spot on the arrays. Time-of-flight spectra were generated using a PCS-4000 mass spectrometer (Bio-Rad). Low-range spectra (mass/charge (m/z) ratio 0 – 20,000) were obtained at a laser energy of 3000 nJ, with a focus mass of 6000 and the matrix attenuated to 1000. High-range spectra (m/z 10,000 – 75,000) were obtained at a laser energy of 3900 nJ, with a focus mass of 30,000 and the matrix attenuated to 10,000. Mass accuracy was calibrated externally using All-in-One Peptide or Protein molecular mass standards (Bio-Rad).

Proteomics data processing

Spectra were analysed using ProteinChip Data Manager (Bio-Rad version 4.1.0) and normalized using total ion current. Peaks were auto-detected using a peak threshold of 12.5% and a mass window of 0.3%, and the resulting data were converted for subsequent analysis using R software. The abundance (intensity) of a given protein peak was quantified as the area under the peak; peak intensities were log-transformed before analysis. After exclusion of one contaminated sample and 4 technical failures, the proteomics data consisted of 470 spectra from 138 patients.

Protein enrichment and identification

Ten µL serum were applied to Top 12 Abundant Protein Depletion Spin Columns (Thermo Scientific Pierce) according to the manufacturer's protocol. Five hundred µL of the eluate were concentrated on a 3 kDa molecular weight cut-off column (Amicon) in 25 mM Tris-HCl, pH 8.0. Twenty µL of depleted serum were separated by 1D SDS-PAGE on an 18% Tris-glycine denaturing gel (TGX, Bio-Rad) at 150 V for 70 min and compared against SeeBlue Plus 2 pre-stained protein standard (Life Technologies). The gel was rinsed 5 times with deionized water and stained overnight in See Band staining solution (Gene Bio-Application Ltd.) A band

corresponding to 15 to 16 kDa was excised and an in-gel trypsin digest¹³ was carried out.

Samples were analysed by nanoscale liquid chromatography-electrospray ionization tandem mass spectrometry (LC-MS/MS), using a nanoAcquity UPLC system (Waters MS Technologies, Manchester, UK). Peptide identification was performed using ProteinLynx Global SERVER v3.1 (Waters).

Serum haemoglobin concentration

Free haemoglobin levels were assayed by ELISA (Abcam ab157707) according to the manufacturer's protocol. Samples were analysed in random order, and staff were blinded to the treatment arms. Absorbance was measured at 450 nm on a SpectraMax microplate reader (Molecular Devices).

Serum lactate dehydrogenase (LDH) activity

Serum LDH activity was assayed by the conversion of lactate to pyruvate, using the absorption of light at 340 nm by the reaction product NADH (Abbott Laboratories, ref. 7D69).

Statistics

All statistical models were carried out using R software¹⁴. To test for associations between SELDI-TOF mass spectrometry peak intensity changes and treatment group, linear regression models were fitted separately for each spectral peak at each follow-up time (6, 12 and 24 months), modelling log(peak intensity change from baseline) as a function of baseline log(peak intensity), treatment group, and the five randomization variables (age, gender, EDSS [Expanded Disability Severity Scale], neuroscience centre, and assessing physician).

To test for associations between peak intensity changes and brain volume changes, for each pair of time points (0–12 months, 0–25 months and 12–25 months) the BBSI was compared with the change in each peak intensity. Linear regression was used to model the log(change in peak intensity) as a function of BBSI (expressed as a percentage of baseline whole-brain volume), adjusted for baseline log(peak intensity), MRI centre, and the five randomization variables.

For both treatment and brain volume analyses, sensitivity analysis was carried out using repeated-measures models including all four time points. Protein peaks whose regression coefficients differed significantly from zero (Wald test) were selected for further analysis. To take into account multiple testing, the p-value for each peak was converted into the False Discovery Rate (FDR: expected proportion of false positives) for that p-value threshold, using the R package *fdrtool*¹⁵. Peaks at $FDR \leq 0.2$ were retained for further analysis.

The results of the haemoglobin ELISA and the serum LDH assay were analysed using two-tailed Mann-Whitney tests to test for pairwise differences between the subject groups.

Results

Intensity of specific protein peaks was associated with change in brain volume

Expression-difference mapping of all longitudinal serum samples (peak threshold of 12.5%; mass window of 0.3% minimum) resulted in detection of 145 peaks that were differentially expressed within individual subjects over time.

To determine whether changes in protein levels (SELDI-TOF peak intensity) were associated with simvastatin treatment, we ran regression models for the change in each protein peak intensity vs. treatment status, adjusting for the 5 randomization variables and MRI centre. No association remained significant after adjusting for multiple comparisons (the lowest level at which the FDR could be controlled was 0.3).

We next ran regression models for change in protein intensity v. brain volume loss, for each interval in which the BBSI was measured (0 to 12 months; 12 to 25 months) and over the whole trial period (0 to 25 months). The changes in intensity of peaks at $m/z = 25,110$ and $25,402$ were significantly associated with the change in brain volume between baseline and 12 months ($p=0.001$, corresponding to $FDR = 0.08$). The regression coefficients for the association were negative, i.e. an increase in these protein intensities was associated with a smaller decrease in brain volume. The change in intensity of the peaks at $m/z = 15,141$ and $15,885$ between baseline and 25 months was significant in each case ($p=0.003$ and 0.001 respectively), corresponding to a FDR of 0.2. For these peaks the regression coefficients were positive, i.e. an increase in these peaks was associated with a larger decrease in brain volume (Figure 1). There were no significant regression coefficients for the 12 to 25 month time period. Repeated-measures models for the whole time period of the trial also identified the peaks at $m/z = 15,141$ and $15,885$ as significant at an FDR of 0.2.

Multiple regression analysis, modelling brain volume change as a function of protein peak intensity, treatment status, and the five randomization variables and MRI centre as covariates confirmed (Table 1) that simvastatin treatment and the protein peak intensity were independently associated with the rate of brain atrophy.

The multiple regression model (Table 1) explained 25% of the observed variation in the rate of brain atrophy over the two-year observation period; the protein peak at 15.1 kDa alone explained 10% of this variation. The regression coefficient of -0.6 for simvastatin treatment indicates a mean difference in brain atrophy rate between treatment groups of -0.6% over the 2-year trial period; this estimate (-0.3%/year) is consistent with the rate of -0.25%/year previously reported in the MS-STAT trial¹. The regression coefficient of 0.75 for BBSI v. protein change means that two patients whose protein increases differ by 30% have an expected difference in brain atrophy rate of 0.1% over two years (the patient with higher increase in protein 15.1kDa expects a greater decrease in brain volume).




Figure 1. Change in intensity of 15.1 kDa peak correlated with rate of brain atrophy. Normalized log(change in intensity of 15.1 kDa peak between baseline and 2-year follow-up) versus percentage decrease in brain volume between baseline and 2 years. Solid line shows the best fit from the linear regression model (regression coefficient = 0.12, $p=0.001$). Protein ratios were normalized to all other covariates, using the linear regression model. Crosses represent treated individuals, circles represent untreated individuals. The correlation with the 15.9 kDa peak was closely similar (regression coefficient = 0.12, $p=0.001$).

Table 1. Multiple linear regression analysis of the association between change in brain volume and change in the peak intensity of the proteins whose changes were found to be significantly correlated with change in brain volume. Beta = regression coefficient. The model is adjusted for the 5 randomization variables and MRI centre.

	m/z 15885 (0 to 25 months)		m/z 15141 (0 to 25 months)	
	Beta (95% CI)	p	Beta (95% CI)	p
protein	0.83 (0.33, 1.33)	0.001	0.75 (0.29, 1.22)	0.002
treatment	-0.62 (-1.06, -0.19)	0.005	-0.60 (-1.03, -0.17)	0.007
	m/z 25110 (0 to 12 months)		m/z 25402 (0 to 12 months)	
	Beta (95% CI)	p	Beta (95% CI)	p
protein	-0.99 (-1.72, -0.26)	0.008	-0.73 (-1.37, -0.09)	0.025
treatment	-0.26 (-0.56, -0.04)	0.090	-0.27 (-0.58, -0.04)	0.083

Identification of proteins associated with brain atrophy

After enrichment, the intensity of the protein peaks at 25.1 kDa and 25.4 kDa remained insufficient to allow their isolation and identification. However, the peaks at 15.1 kDa and 15.9 kDa remained at high intensities and distinct from nearby peaks (Figure 2). LC-MS/MS identified twenty-six peptide fragments matching human proteins: 15 fragments corresponded to human α -haemoglobin and the remaining 11 fragments corresponded to β -haemoglobin (Table 2; Supplementary Table 1). Of the remaining

364 sequence matches (after exclusion of bacterial sequences and the common contaminant keratin), the top 360 were partial matches to haemoglobin subunits of other mammalian species.

ELISA confirms the presence of free serum haemoglobin in MS patients

We assayed free haemoglobin by ELISA in MS patients ($n=20$) and in three control groups ($n=20$ in each group; Materials and Methods). The results (Figure 3A) showed significantly higher

concentrations of free haemoglobin in the serum from MS patients, when compared to each control group ($p < 0.001$ in each comparison; Mann-Whitney). Of the 20 MS patients assayed, 17 had a serum haemoglobin concentration greater than the mean + 2 standard errors of the healthy adult controls. No significant difference was observed between the three control groups.

Abnormally high serum LDH activity in MS patients

The presence of free haemoglobin in the serum in MS patients suggested a degree of intravascular haemolysis in these individuals. To seek corroborative evidence of haemolysis, we assayed

the serum LDH activity. The median LDH activity in the patients with MS was significantly greater than that in each of the three control groups (Figure 3B; $p < 10^{-12}$ in each case; Mann-Whitney); no significant difference was found between the three control groups, in each of which the LDH was within the normal range.

The mean erythrocyte count, haematocrit and total blood haemoglobin in the cohort were within the normal range (see Data availability), and there was no association between these parameters and the rate of brain atrophy.




Figure 2. SELDI-TOF mass spectrometry spectra of 15.1 kDa and 15.9 kDa protein peaks. (A.) Following enrichment on Top 12 Protein Depletion column and (B.) Concentration of eluate on 3 kDa molecular weight cutoff column.

Table 2. Identification of peptide fragments from 15.1 kDa and 15.9 kDa protein peaks, using LC-MS/MS. *oxidation of M(1). **oxidation of M(15).

Peak	m/z	Protein name	Accession no. (UniProt)	PLGS score	Peptide matches
1	15,141	Haemoglobin alpha	P69905	2049	(R)VDPVNFK(L) (R)MFLSFPTTK(T)* (K)VGGHAAEYGAEALER(M) (R)MFLSFPTTK(T)
2	15,885	Haemoglobin beta	P68871	2579	(R)FFESFGDLSTPDVGMGNPK(V)** (R)LLVVYPWTQR(F) (K)EFTPPVQAAYQK(V) (R)FFESFGDLSTPDVGMGNPK(V) (K)LHVDPENFR(L)




Figure 3. Free serum haemoglobin and lactate dehydrogenase are raised in secondary progressive multiple sclerosis. A. Serum haemoglobin concentration measured by ELISA in asymptomatic carriers of HTLV-1 (AC), patients with HTLV-1-associated myelopathy (HAM), uninfected, healthy controls (HC), and patients with secondary progressive MS. Log [haemoglobin] by ELISA was significantly correlated with log(peak intensity): $r = 0.52$; $p = 0.02$; linear regression. **B.** Serum lactate dehydrogenase (LDH) activity in the same groups of subjects.

Discussion

The characteristic pathological feature of early, active multiple sclerosis lesions is primary demyelination, with partial preservation of axons. But the dominant feature in progressive disease is neurodegeneration, which results in brain atrophy. Factors associated with this neurodegeneration⁵ include microglial activation, chronic oxidative injury, mitochondrial damage in axons, and iron accumulation. A strong correlate of neurodegeneration in MS is abnormal iron deposition in both grey and white matter in MS, especially along veins and venules in cerebral MS plaques^{16,17}. Iron can potentiate oxidative damage by generating hydroxyl radicals by the Fenton reaction. The extent of iron accumulation, as

indicated by T2 signal hypointensity on MRI, is correlated with disease progression, lesion accumulation and cell death of oligodendrocytes^{18–20}. The extent of iron deposition is greater in SPMS than in relapsing-remitting disease¹⁸.

The source of this abnormal iron deposited in the central nervous system in MS is unknown. Iron is liberated from damaged oligodendrocytes and myelin²¹ and accumulates in macrophages and microglia at the margin of active lesions, but it remains unclear whether this is the principal source of the iron that accumulates in the vessel walls and perivascular space. Bamm and Harauz²² proposed that chronic extravasation of red blood cells is a source

of the abnormal iron deposits; however, neuropathological evidence does not show frequent or widespread extravascular erythrocytes in the MS brain.

The results presented here show that a rise in the concentration of free haemoglobin in the serum was associated with the rate of brain atrophy in this cohort of patients with SPMS. This effect was independent of the beneficial treatment effect of simvastatin, because there was no association between free haemoglobin concentration and simvastatin treatment. Since a successful response to simvastatin treatment was not associated with the free serum haemoglobin concentration, we infer that the change in free serum haemoglobin was not a consequence of brain atrophy but preceded brain atrophy in the causal pathway.

These results suggest the hypothesis that chronic, low-grade intravascular haemolysis releases haemoglobin into the serum, which is then translocated into the CNS parenchyma across the impaired blood-brain barrier and potentiates oxidative damage to oligodendrocytes. Cytotoxicity by free haemoglobin can be mediated by intact haemoglobin itself, by haem, or by iron, especially as Fe^{2+} ²². Free haemoglobin is degraded by haem oxygenase-1 (HO-1), producing biliverdin and Fe^{2+} ions. HO-1 is upregulated in glia by oxidative stress, and HO-1 is expressed in oligodendrocytes in actively demyelinating areas in MS, but not in two other CNS diseases, human acute disseminated leukoencephalomyelitis (ADEM) or murine experimental allergic encephalomyelitis (EAE)²³. Stahnke *et al.*²³ proposed that the role of stress-induced HO-1 is protective initially, whereas chronic upregulation might cause oligodendrocyte death.

The observation (Figure 3B) of abnormally high serum LDH activity is consistent with the presence of haemolysis in these patients. LDH is present in all cell types, and serum LDH is raised in many inflammatory conditions; however, erythrocytes are particularly rich in LDH, and serum LDH is a sensitive marker of haemolysis. The notion that chronic intravascular haemolysis might serve as a source of the iron deposited in MS is also consistent with earlier reports of abnormal fragility of erythrocytes. Erythrocytes from patients with MS, especially those with active disease, are abnormally susceptible to lysis by both mechanical stress²⁴ and osmotic stress²⁵. The causes of this erythrocyte fragility remain to be identified. Possible artefactual causes of haemolysis, such as venepuncture, cannot explain the significant association observed here between brain atrophy and free serum haemoglobin.

If intravascular haemolysis indeed occurs in SPMS, the rate of red cell destruction is insufficient to reduce the total blood haemoglobin, which remained within normal limits in this cohort. Neurodegeneration is not a feature of other chronic haemolytic conditions, such as spherocytosis or elliptocytosis; however, in these conditions the blood-brain barrier is intact, and most erythrocyte destruction occurs in the spleen, where efficient phagocytosis may prevent the release of the toxic breakdown products into the circulation.

Polymorphisms in genes encoding iron-binding and iron-transporting proteins are associated with disability, disease severity and early progression in MS²⁶. Rithidech *et al.*²⁷ used 2D electrophoresis to identify plasma biomarkers in paediatric MS: the

haem-binding protein haemopexin was 1 of 12 proteins found to be upregulated in 9 MS patients. Robotti *et al.*²⁸ identified an alteration in the ratio of isoforms of haptoglobin (which bind free haemoglobin) in MS.

These results do not suggest that free serum haemoglobin concentration is useful in the differential diagnosis of neurological disease; rather, they identify a potential contributor to the pathogenesis of neurodegeneration in progressive multiple sclerosis.

Previous studies of serum iron have shown normal concentrations in the serum in patients with MS²⁹; however, standard assays of free serum iron do not detect iron that is sequestered in haemoglobin. Iron chelation has been proposed as a therapy to approach to reduce neurodegeneration in MS. However, if an important source of iron is free serum haemoglobin, standard iron-chelating agents such as desferrioxamine will be ineffective, again because the iron is sequestered in haemoglobin³⁰. Scavengers of haemoglobin and haemin³¹ might be more effective.

Data availability

Zenodo: Raw data for SELDI-TOF low range from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis, <http://doi.org/10.5281/zenodo.160737>³²

Zenodo: Raw data for SELDI-TOF high range from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis, <http://doi.org/10.5281/zenodo.160743>³³

Zenodo: Nano LC MS-MS peptide matches from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis, <http://doi.org/10.5281/zenodo.160744>³⁴

Zenodo: Raw data for RBC, Hb and haematocrit from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis, <http://doi.org/10.5281/zenodo.161532>³⁵

Author contributions

AL analysed data, wrote the manuscript; SH designed experiments, conducted experiments, analysed data, wrote the manuscript; AW designed experiments, conducted experiments, analysed data.; PL designed experiments, wrote the manuscript; RN designed experiments, wrote the manuscript; JC designed MS-STAT trial, designed experiments, wrote the manuscript; CB conceived the project, designed experiments, analysed data, wrote the manuscript.

Competing interests

No competing interests were disclosed.

Grant information

This work was supported by the Wellcome Trust [100291]; Medical Research Council [MR K019090]; National Institute of Health Research; University College London Hospitals/UCL Biomedical Research Centre.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

We thank the participants in the MS-STAT trial; Alan Courtney and the staff of the Clinical Biochemistry Laboratory of Imperial College NHS Hospital Trust for carrying out the LDH assays; and

Hal Drakesmith for helpful discussion. The analysis of the MRI data in the previously reported MS-STAT trial was carried out by Nick Fox (University College London), Jennifer Nicholas and Chris Frost (London School of Hygiene and Tropical Medicine).

Supplementary material

[Supplementary Table 1. Protein peaks associated with brain atrophy: identification by liquid chromatography-electrospray ionization tandem mass spectrometry.](#)

Relative molecular mass, protein score and identity of the genes with sequence matches to peptide fragments from the protein peaks that were significantly correlated with the rate of brain atrophy. The common contaminant keratin and partial matches to contaminating bacterial sequences were excluded.

References

- Chataway J, Schuerer N, Alsanousi A, *et al.*: **Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.** *Lancet*. 2014; **383**(9936): 2213–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kappos L, Li D, Calabresi PA, *et al.*: **Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.** *Lancet*. 2011; **378**(9805): 1779–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ontaneda D, Fox RJ, Chataway J: **Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.** *Lancet Neurol*. 2015; **14**(2): 208–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Plantone D, De Angelis F, Doshi A, *et al.*: **Secondary Progressive Multiple Sclerosis: Definition and Measurement.** *CNS drugs*. 2016; **30**(6): 517–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Mahad DH, Trapp BD, Lassmann H: **Pathological mechanisms in progressive multiple sclerosis.** *Lancet Neurol*. 2015; **14**(2): 183–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Reynolds R, Roncaroli F, Nicholas R, *et al.*: **The neuropathological basis of clinical progression in multiple sclerosis.** *Acta Neuropathol*. 2011; **122**(2): 155–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kapoor R, Furby J, Hayton T, *et al.*: **Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.** *Lancet Neurol*. 2010; **9**(7): 681–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gnanapavan S, Grant D, Morant S, *et al.*: **Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.** *PLoS One*. 2013; **8**(8): e70019.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Paling D, Solanky BS, Riemer F, *et al.*: **Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.** *Brain*. 2013; **136**(Pt 7): 2305–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Liguori M, Qualtieri A, Tortorella C, *et al.*: **Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration.** *PLoS One*. 2014; **9**(8): e103984.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Teunissen CE, Koel-Simmeling MJ, Pham TV, *et al.*: **Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.** *Mult Scler*. 2011; **17**(7): 838–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Tremlett H, Dai DL, Hollander Z, *et al.*: **Serum proteomics in multiple sclerosis disease progression.** *J Proteomics*. 2015; **118**: 2–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Shevchenko A, Wilm M, Vorm O, *et al.*: **Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels.** *Anal Chem*. 1996; **68**(5): 850–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- R Core Team: **R: A language and environment for statistical computing.** R Foundation for Statistical Computing, Vienna, Austria. 2013.
[Reference Source](#)
- Strimmer K: **fdrtool: a versatile R package for estimating local and tail area-based false discovery rates.** *Bioinformatics*. 2008; **24**(12): 1461–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Adams CW: **Perivascular iron deposition and other vascular damage in multiple sclerosis.** *J Neurol Neurosurg Psychiatry*. 1988; **51**(2): 260–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Williams R, Buchheit CL, Berman NE, *et al.*: **Pathogenic implications of iron accumulation in multiple sclerosis.** *J Neurochem*. 2012; **120**(1): 7–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bakshi R, Shaikh ZA, Janardhan V: **MRI T2 shortening ('black T2') in multiple sclerosis: frequency, location, and clinical correlation.** *Neuroreport*. 2000; **11**(1): 15–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Brass SD, Benedict RH, Weinstock-Guttman B, *et al.*: **Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis.** *Mult Scler*. 2006; **12**(4): 437–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Neema M, Arora A, Healy BC, *et al.*: **Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis.** *J Neuroimaging*. 2009; **19**(1): 3–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hametner S, Wimmer I, Haider L, *et al.*: **Iron and neurodegeneration in the multiple sclerosis brain.** *Ann Neurol*. 2013; **74**(6): 848–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bamm VV, Harauz G: **Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders?** *Cell Mol Life Sci*. 2014; **71**(10): 1789–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Stahnke T, Stadelmann C, Netzler A, *et al.*: **Differential upregulation of heme oxygenase-1 (HSP32) in glial cells after oxidative stress and in demyelinating disorders.** *J Mol Neurosci*. 2007; **32**(1): 25–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Schauf CL, Frischer H, Davis FA: **Mechanical fragility of erythrocytes in multiple sclerosis.** *Neurology*. 1980; **30**(3): 323–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kurantsin-Mills J, Samji N, Moscarello MA, *et al.*: **Comparison of membrane structure, osmotic fragility, and morphology of multiple sclerosis and normal erythrocytes.** *Neurochem Res*. 1982; **7**(12): 1523–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gemmati D, Zeri G, Orioli E, *et al.*: **Polymorphisms in the genes coding for iron binding and transporting proteins are associated with disability, severity, and early progression in multiple sclerosis.** *BMC Med Genet*. 2012; **13**: 70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Rithidech KN, Honikel L, Milazzo M, *et al.*: **Protein expression profiles in pediatric multiple sclerosis: potential biomarkers.** *Mult Scler*. 2009; **15**(4): 455–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Robotti A, Natale M, Albo AG, *et al.*: **Acute-phase proteins investigation based**

- on lectins affinity capture prior to 2-DE separation: application to serum from multiple sclerosis patients. *Electrophoresis*. 2010; 31(17): 2882–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. LeVine SM, Lynch SG, Ou CN, *et al.*: Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. *Brain Res*. 1999; 821(2): 511–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Weigel KJ, Lynch SG, LeVine SM: Iron chelation and multiple sclerosis. *ASN Neuro*. 2014; 6(1): e00136.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 31. Schaer DJ, Buehler PW, Alayash AI, *et al.*: Hemolysis and free hemoglobin revisited: exploring hemoglobin and heme scavengers as a novel class of therapeutic proteins. *Blood*. 2013; 121(8): 1276–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. Lewin A, Hamilton S, Witkover A, *et al.*: Raw data for SELDI-TOF low range from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. *Zenodo*. 2016.
[Data Source](#)
 33. Lewin A, Hamilton S, Witkover A, *et al.*: Raw data for SELDI-TOF high range from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. *Zenodo*. 2016.
[Data Source](#)
 34. Lewin A, Hamilton S, Witkover A, *et al.*: Nano LC MS-MS peptide matches from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. *Zenodo*. 2016.
[Data Source](#)
 35. Lewin A, Hamilton S, Witkover A, *et al.*: Raw data for RBC, Hb and haematocrit from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. *Zenodo*. 2016.
[Data Source](#)